Sign Up
Stories
Biotech Stocks' 2024 Outlook
Share
ABIO ARCA Revenue Analysis
ADR Surge and Drops in NY
AHF Criticizes Gilead Sciences for Profi...
Amgen's Weight-Loss Drugs Market Entranc...
Avid Bioservices Financial Turmoil
Biotech Investment Amidst Rate Cuts
Overview
API
Biotech stocks ILMN, PLX, and ALNY show promising potential for gains in 2024, driven by positive financial performance and strategic partnerships. ILMN has exhibited revenue and EPS growth, while PLX boasts strong asset turnover and EBITDA margins. ALNY focuses on gene editing and collaborations with Janssen Research & Development. The industry's positive outlook and financial performance of these companies indicate potential for gains in 2024.
Ask a question
How do the strategies and collaborations of ILMN, PLX, and ALNY align with the broader trends and innovations in the biotech industry?
How might the COVID-19 pandemic's impact on the biotech industry affect the potential gains for ILMN, PLX, and ALNY in 2024?
What are the potential risks or challenges that could hinder the growth and profitability of these biotech stocks?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Coverage